http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-069752-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_80eb35630ae5a11f603db5175804fe2d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
| filingDate | 2008-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-069752-A1 |
| titleOfInvention | COMPOSITIONS THAT INCLUDE NICOTINIC AGONISTS AND ITS USE AND KIT |
| abstract | The compositions are useful, for example, for the treatment of disorders, diseases or conditions of the central nervous system and to induce smoking cessation. Claim 1: A pharmaceutical composition comprising a nicotinic agonist and an inhibitor of desensitization of the nicotinic acetylcholine receptor (nAChR), and a carrier acceptable for pharmaceutical use. Claim 2: The pharmaceutical composition according to claim 1, wherein the nicotinic agonist is selected from: nicotine, nicotine metabolites, decametonium bromide, epibatidine, lobelin, varenicline, epiboxidine, epiquinamide; ABT 418, ABT-594, DMXB-A, SlB-1508 (altinicline); and RJR 2403 (methanicotine), and its salts and isomers acceptable for pharmaceutical use, where nicotine metabolites are selected from cotinine, nornicotine, norcotinine, N-oxide of nicotine, N-oxide of cotinine, 3-hydroxy-cotinine, 5 -hydroxy-cotinine and its salts acceptable for pharmaceutical use. Claim 3: The pharmaceutical composition according to claim 1 or 2, wherein the nAChR desensitization inhibitor is selected from ionic channel inhibitors, sodium channel inhibitors, potassium channel inhibitors, channel inhibitors calcium, beta blockers, sigma receptor antagonists, norepinephrine (NE) reuptake inhibitors, selective serotonin reuptake inhibitors, and muscarinic agonists, adenosine antagonists, kappa-opioid agonists, dopamine receptor antagonists and / or serotonin, neurosteroids, sigma 1 receptor agonists, and galantamine, an acetylcholine esterase inhibitor. Claim 4: The pharmaceutical composition according to claim 3, wherein said ionic channel inhibitors include lidocaine and mepivacaine; such sodium channel inhibitors include phenytoin, carbamazepine, lamotrigine, quinidine, procainamide, disopyramide, mexiletine, tocainide, flecainide, and propafenone; such potassium channel inhibitors include nibetan, sotalol, amiodarone, and bretilium; said calcium channel inhibitors include verapamil and diltiazem; said beta blockers include propranolol, timolol, atenolol, and metoprolol; said sigma receptor antagonists include opipramol and rimcazol; such NE reuptake inhibitors include dosulepine, lofepramine, nortriptyline, and protriptyline; said selective serotonin reuptake inhibitors include clomipramine; such muscarinic agonists include McN-A-343, arecoline, cevimeline (AF-102B), AF-150, and AF-267B; said adenosine antagonists include caffeine; said kappa-opioid agonists include codeine and pentazocine; such dopamine and / or serotonin receptor antagonists include clozapine, docosahexaenoic acid (DHA), and quetipine; said neurosteroids include alfaxolone and minaxolone; and said sigma 1 receptor agonists include pentazocine. |
| priorityDate | 2007-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 149.